• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Ursula A. Matulonis, MD


  • Choi YE, Battelli C, Watson J, Liu J, Curtis J, Morse AN, Matulonis UA, Chowdhury D, Konstantinopoulos PA.Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells.Oncotarget. 2014 May 15;5(9):2678-87.
  • Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS.Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance.J Clin Invest. 2014 Jun 2(6):2611-25.
  • Liu JF, Konstantinopoulos PA, Matulonis UA.PARP inhibitors in ovarian cancer: Current status and future promise.Gynecol Oncol. 2014 May;133(2):362-369.
  • Picard M, Matulonis UA, Castells M.Chemotherapy hypersensitivity reactions in ovarian cancer.J Natl Compr Canc Netw. 2014 Mar 1;12(3):389-402.
  • Viswanathan AN, Lee H, Berkowitz R, Berlin S, Campos S, Feltmate C, Horowitz N, Muto M, Sadow CA, Matulonis U.A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer.Gynecol Oncol. 2014 Jan;132(1):55-60.
  • Lee LJ, Demaria R, Berkowitz R, Matulonis U, Viswanathan AN.Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen.Gynecol Oncol. 2014 Jan;132(1):65-9.
  • Konstantinopoulos PA, Matulonis UA.Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer.Frontiers In Oncology. 2013;3:296.
  • Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC.Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.PLoS ONE. 2013;8(11):e80023.
  • Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes M.Ovarian cancer, version 2.2013.J Natl Compr Canc Netw. 2013 Oct 1;11(10):1199-209.
  • Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, Macconaill LE, Shoni M, Wagle N, Jones RT, Quick CM, Laury A, Katz IT, Hahn WC, Matulonis UA, Hirsch MS.Oncogenic mutations in cervical cancer: Genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.Cancer. 2013 Nov 1;119(21):3776-83.
  • Liu JF, Kindelberger D, Doyle C, Lowe A, Barry WT, Matulonis UA.Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients.Gynecol Oncol. 2013 Aug 13.
  • Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA.A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.Eur J Cancer. 2013 Sep;49(14):2972-8.
  • Townamchai K, Berkowitz R, Bhagwat M, Damato AL, Friesen S, Lee LJ, Matulonis U, O'Farrell D, Viswanathan AN.Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer.Gynecol Oncol. 2013 Apr;129(1):18-21.
  • Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA.Ovarian Cancer, Version 3.2012.J Natl Compr Canc Netw. 2012 Nov 1;10(11):1339-1349.
  • McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS, Chin KT, Partridge JC, Poole BB, Cheng KH, Daggett J, Cullen K, Kantoff E, Hasselbatt K, Berkowitz J, Muto MG, Berkowitz RS, Aster JC, Matulonis UA, Dinulescu DM.Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy.Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):E2939-48.
  • Gross AH, Cromwell J, Fonteyn M, Matulonis UA, Hayman LL.Hopelessness and Complementary Therapy Use in Patients With Ovarian Cancer.Cancer Nurs. 2012 Oct 18.
  • Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, Defazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD, , Matulonis UA.Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome.Clin Cancer Res. 2012 Oct 15;18(20):5806-5815.
  • Matulonis UA, Sharma S, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I, Kutarska E, Liu H, Fingert H, Zhou X, Danaee H, Schilder RJ.Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.Gynecol Oncol. 2012 Oct;127(1):63-9.
  • Matulonis UA, Lee J, Lasonde B, Tew WP, Yehwalashet A, Matei D, Behbakht K, Grothusen J, Fleming G, Lee NK, Arnott J, Bray MR, Fletcher G, Brokx RD, Castonguay V, Mackay H, Sidor CF, Oza AM.ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer.Eur J Cancer. 2012 Aug 21.
  • Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, Pereira L, Tyburski K, Roche M, Szymonifka J, Berlin S.A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma.Gynecol Oncol. 2012 Aug 9.
  • Campos SM, Berlin S, Matulonis UA, Muto MG, Pereira L, Mosquera MM, Horowitz N.Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function.J Psychosoc Oncol. 2012;30(4):387-401.
  • Matulonis UA, Pereira L, Liu J, Lee H, Lee J, Whalen C, Campos S, Atkinson T, Hill M, Berlin S.Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer.Gynecol Oncol. 2012 Jul;126(1):41-6.
  • Matulonis UA.Bevacizumab and its use in epithelial ovarian cancer.Future Oncol. 2011 Mar;7(3):365-79.
  • Morgan RJ, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner TL.Epithelial ovarian cancer.J Natl Compr Canc Netw. 2011 Jan;9(1):82-113.
  • Cramer DW, O'Rourke DJ, Vitonis AF, Matulonis UA, Dijohnson DA, Sluss PM, Crum CP, Liu BC.CA125 Immune Complexes in Ovarian Cancer Patients with Typical CA125 Concentrations.Clin Chem. 2010 Dec;56(12):1889-92.
  • Wright AA, Keating NL, Balboni TA, Matulonis UA, Block SD, Prigerson HG.Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health.J Clin Oncol. 2010 Oct 10;28(29):4457-64.
  • Wright AA, Mack JW, Kritek PA, Balboni TA, Massaro AF, Matulonis UA, Block SD, Prigerson HG.Influence of patients' preferences and treatment site on cancer patients' end-of-life care.Cancer. 2010 Oct 1;116(19):4656-63.
  • Kornblith AB, Mirabeau-Beale K, Lee H, Goodman AK, Penson RT, Pereira L, Matulonis UA.Long-term adjustment of survivors of ovarian cancer treated for advanced-stage disease.J Psychosoc Oncol. 2010 Sep;28(5):451-69.
  • Liu J, Matulonis UA.New advances in ovarian cancer.Oncology (Huntingt). 2010 Jul;24(8):721-8. Review.
  • Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN.Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer.Int J Clin Oncol. 2010 Aug;15(4):390-8.
  • Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A.Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.Lancet. 2010 Jul 24;376(9737):245-51.
  • Dean-Clower E, Doherty-Gilman AM, Keshaviah A, Baker F, Kaw C, Lu W, Manola J, Penson RT, Matulonis UA, Rosenthal DS.Acupuncture as Palliative Therapy for Physical Symptoms and Quality of Life for Advanced Cancer Patients.Integr Cancer Ther. 2010 Jun;9(2):158-67.
  • Robinson ES, Matulonis UA, Ivy P, Berlin ST, Tyburski K, Penson RT, Humphreys BD.Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.Clin J Am Soc Nephrol. 2010 Mar;5(3):477-83.
  • Clauss A, Ng V, Liu J, Piao H, Russo M, Vena N, Sheng Q, Hirsch MS, Bonome T, Matulonis U, Ligon AH, Birrer MJ, Drapkin R.Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival.Neoplasia. 2010 Feb;12(2):161-72.
  • Roche MR, Rudd PJ, Krasner CN, Matulonis UA, Berlin ST, Lee H, Silver M, Tran CD, Seiden MV, Penson RT.Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors.Gynecol Oncol. 2010 Feb;116(2):168-72.
  • Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM.Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.J Clin Oncol. 2010 Jan 1;28(1):154-9.
  • April C, Klotzle B, Royce T, Wickham-Garcia E, Boyaniwsky T, Izzo J, Cox D, Jones W, Rubio R, Holton K, Matulonis U, Quackenbush J, Fan JB.Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples.PLoS ONE. 2009;4(12):e8162.
  • Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT.Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.J Clin Oncol. 2009 Nov 20;27(33):5601-6.
  • Liu JF, Hirsch MS, Lee H, Matulonis UA.Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.Gynecol Oncol. 2009 Dec;115(3):401-6.
  • Lu W, Matulonis UA, Doherty-Gilman A, Lee H, Dean-Clower E, Rosulek A, Gibson C, Goodman A, Davis RB, Buring JE, Wayne PM, Rosenthal DS, Penson RT.Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial.J Altern Complement Med. 2009 Jul;15(7):745-53.
  • Mirabeau-Beale KL,Kornblith AB,Penson RT,Lee H,Goodman A,Campos SM,Duska L,Pereira L,Bryan J,Matulonis UA.Comparison of the quality of life of early and advanced stage ovarian cancer survivors.Gynecol Oncol. 2009 Aug;114(2):353-9.
  • Matulonis UA, Kornblith A, Lee H, Bryan J, Gibson C, Wells C, Lee J, Sullivan L, Penson R.Long-term adjustment of early-stage ovarian cancer survivors.Int J Gynecol Cancer.;18(6):1183-93.
  • Matulonis UA,Krag KJ,Krasner CN,Atkinson T,Horowitz NS,Lee H,Penson RT.Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Mullerian tumors.Gynecol Oncol. 2009 Feb;112(2):394-9.
  • Callahan MJ,Nagymanyoki Z,Bonome T,Johnson ME,Litkouhi B,Sullivan EH,Hirsch MS,Matulonis UA,Liu J,Birrer MJ,Berkowitz RS,Mok SC.Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer.Clin Cancer Res. 2008 Dec 1;14(23):7667-73.
  • Matulonis UA,Horowitz NS,Campos SM,Lee H,Lee J,Krasner CN,Berlin S,Roche MR,Duska LR,Pereira L,Kendall D,Penson RT.Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.J Clin Oncol. 2008 Dec 10;26(35):5761-6.
  • Castells MC,Tennant NM,Sloane DE,Hsu FI,Barrett NA,Hong DI,Laidlaw TM,Legere HJ,Nallamshetty SN,Palis RI,Rao JJ,Berlin ST,Campos SM,Matulonis UA.Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.J Allergy Clin Immunol. 2008 Sep;122(3):574-80.
  • Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W.Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.J Clin Oncol. 2007 Nov 20;25(33):5180-6.
  • Seiden MV, Burris HA, Matulonis U, Hall JB, Armstrong DK, Speyer J, Weber JD, Muggia F.A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies.Gynecol Oncol. 2007 Mar;104(3):727-31.
  • Littell RD, Hallonquist H, Matulonis U, Seiden MV, Berkowitz RS, Duska LR.Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian, tubal, and primary peritoneal carcinoma.Gynecol Oncol. 2006 Nov;103(2):570-4.
  • Matulonis UA, Campos S, Krasner CN, Duska LR, Penson RT, Falke R, Roche M, Smith LM, Lee H, Seiden MV, ,.Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: The modified triple doublet regimen.Gynecol Oncol. 2006 Nov;103(2):575-80.
  • Matulonis UA, Campos S, Duska L, Krasner CN, Atkinson T, Penson RT, Seiden MV, Verrill C, Fuller AF, Goodman A,.Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer.Gynecol Oncol. 2006 Oct;103(1):160-4.
  • Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY.Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status.J Clin Oncol. 2006 Sep 10;24(26):4324-32.
  • Matulonis UA, Seiden MV, Roche M, Krasner C, Fuller AF, Atkinson T, Kornblith A, Penson R.Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.J Pain Symptom Manage. 2005 Dec;30(6):563-9.
  • Penson RT, Campos SM, Seiden MV, Krasner C, Fuller AF, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA,.A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors.Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1035-41.
  • Seiden MV, Gordon AN, Bodurka DC, Matulonis UA, Penson RT, Reed E, Alberts DS, Weems G, Cullen M, McGuire WP.A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.Gynecol Oncol. 2006 Apr;101(1):55-61.
  • Lee CW, Matulonis UA, Castells MC.Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses.Gynecol Oncol. 2005 Nov;99(2):393-9.
  • Berkenblit A, Matulonis UA, Kroener JF, Dezube BJ, Lam GN, Cuasay LC, Brünner N, Jones TR, Silverman MH, Gold MA.A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial.Gynecol Oncol. 2005 Oct;99(1):50-7.
  • Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D, Nadler LM.Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.Clin Cancer Res. 2005 Jun 15;11(12):4430-6.
  • Feldweg AM, Lee CW, Matulonis UA, Castells M.Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.Gynecol Oncol. 2005 Mar;96(3):824-9.
  • Duska LR, Berkowitz R, Matulonis U, Muto M, Goodman A, McIntyre JF, Klein A, Atkinson T, Seiden MV, Campos S.A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.Gynecol Oncol. 2005 Jan;96(1):198-203.
  • Penson RT, Seiden MV, Goodman A, Fuller AF, Berkowitz RS, Matulonis UA, Krasner C, Lee H, Atkinson T, Campos SM,.Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies.Gynecol Oncol. 2004 Jun;93(3):702-7.
  • Seiden MV, Muggia F, Astrow A, Matulonis U, Campos S, Roche M, Sivret J, Rusk J, Barrett E.A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.Gynecol Oncol. 2004 Apr;93(1):229-32.
  • del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, Penson R, Campos S, Roche M, Seiden MV.Phase II trial of anastrozole in women with asymptomatic müllerian cancer.Gynecol Oncol. 2003 Dec;91(3):596-602.
  • Matulonis U, Campos S, Duska L, Fuller A, Berkowitz R, Gore S, Roche M, Colella T, Lee H, Seiden MV, ,.A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.Gynecol Oncol. 2003 Nov;91(2):293-8.
  • Campos SM, Matulonis UA, Penson RT, Lee H, Berkowitz RS, Duska LR, Fuller AF, Wilson KS, Puchalski TA, Supko JG, Seiden MV.Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors.Gynecol Oncol. 2003 Sep;90(3):610-8.
  • Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, Ette E, Garg V, Fuller A, Harding MW, Charpentier D.A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy.Gynecol Oncol. 2002 Sep;86(3):302-10.
  • Diller L, Medeiros Nancarrow C, Shaffer K, Matulonis U, Mauch P, Neuberg D, Tarbell NJ, Litman H, Garber J.Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study.J Clin Oncol. 2002 Apr 15;20(8):2085-91.
  • Penson RT, Supko JG, Seiden MV, Fuller AF, Berkowitz RS, Goodman A, Campos SM, MacNeill KM, Cook S, Matulonis UA.A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors.Cancer. 2001 Sep 1;92(5):1156-67.
  • Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP.Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.J Clin Oncol. 2001 May 15;19(10):2722-30.
  • Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, Matulonis UA, Muzikansky A, Seiden MV.The clinical utility of liposomal doxorubicin in recurrent ovarian cancer.Gynecol Oncol. 2001 May;81(2):206-12.
  • Tung N, Berkowitz R, Matulonis U, Quartulli M, Seiden M, Kim Y, Niloff J, Cannistra SA.Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.Gynecol Oncol. 2000 May;77(2):271-7.
  • Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP.Docetaxel administered on a weekly basis for metastatic breast cancer.J Clin Oncol. 2000 Mar;18(6):1212-9.
  • Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP.Phase I study of Doxil and vinorelbine in metastatic breast cancer.Ann Oncol. 1999 Sep;10(9):1113-6.
  • Havlin KA, Ramirez MJ, Legler CM, Harris LN, Matulonis UA, Hohneker JA, Hayes DF, Winer EP.Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.Cancer Chemother Pharmacol. 1999;43(1):68-72.
  • Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, Griffin JD.B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct.J Immunol. 1996 Feb 1;156(3):1126-31.
  • Matulonis UA, Dosiou C, Lamont C, Freeman GJ, Mauch P, Nadler LM, Griffin JD.Role of B7-1 in mediating an immune response to myeloid leukemia cells.Blood. 1995 May 1;85(9):2507-15.
  • Okuda K, Matulonis U, Salgia R, Kanakura Y, Druker B, Griffin JD.Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1.Exp Hematol. 1994 Oct;22(11):1111-7.
  • Matulonis UA, Griffin JD, Canellos GP.Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high-dose cytosine arabinoside and melphalan.Am J Hematol. 1994 Apr;45(4):283-7.
  • Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD.Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.Exp Hematol. 1993 Oct;21(11):1460-6.
  • Druker B, Okuda K, Matulonis U, Salgia R, Roberts T, Griffin JD.Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines.Blood. 1992 May 1;79(9):2215-20.